Literature DB >> 16411146

Diffuse sclerosing variant of papillary carcinoma of the thyroid: a 35-year comparative study at a single institution.

Alfred King Yin Lam1, Chung Yau Lo.   

Abstract

BACKGROUND: Diffuse sclerosing variant (DSV) is a rare variant of papillary thyroid carcinoma (PTC), and the features of this carcinoma have not been fully characterized. The aim of this study was to analyze the clinicopathologic features of a large cohort of patients with this disease.
METHODS: We reclassified primary thyroid carcinomas treated in a 35-year study period and studied the clinicopathologic features and outcomes of DSV of PTC in comparison with classic PTC.
RESULTS: Fifteen patients (2 men and 13 women) with DSV of PTC were identified who had surgical resection of the thyroid. Fine-needle aspiration biopsy diagnosed 83% (10 of 12) of the tumors. Compared with classic PTC, patients with DSV presented at a younger age (mean age, 29 vs. 46 years; P = .0001), had larger tumors (mean diameter, 3.6 vs. 2.2 cm; P = .002), and had a higher incidence of cervical nodal metastases (80% vs. 43%; P = .006). Ten patients had received postoperative iodine 131 ablation, and four had also received external-beam irradiation. Distant metastases were detected in two patients (one in lung and one in brain). One third (5 of 15) of the patients developed disease recurrence. Lymph node recurrence was detected in one patient 12 years after the initial operation. Over a median follow-up period of 10.7 years, one patient with an initial incomplete excision died of the carcinoma. The overall disease-specific survival rate was 93%.
CONCLUSIONS: DSV of PTC had distinctive clinicopathologic features and a high incidence of recurrence after operation but had a prognosis similar to that of classic PTC.

Entities:  

Mesh:

Year:  2006        PMID: 16411146     DOI: 10.1245/ASO.2006.03.062

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  22 in total

1.  Different CXCR4 expression according to various histologic subtype of papillary thyroid carcinoma.

Authors:  Dong Yeob Shin; Kwang Joon Kim; Cheol Ryong Ku; Mi Kyung Lee; Soo Il Jee; Woong Youn Chung; Eun Jig Lee
Journal:  Endocr Pathol       Date:  2013-12       Impact factor: 3.943

2.  Miliary lung metastasis due to papillary thyroid carcinoma.

Authors:  Anastasios Gkountouvas; Fotini Chatjimarkou; Dimitrios Thomas; Philippos Kaldrimidis
Journal:  BMJ Case Rep       Date:  2009-02-20

3.  Clinicopathologic features and outcomes in patients with diffuse sclerosing variant of papillary thyroid carcinoma.

Authors:  Junko Akaishi; Kiminori Sugino; Kaori Kameyama; Chie Masaki; Kenichi Matsuzu; Akifumi Suzuki; Takashi Uruno; Keiko Ohkuwa; Hiroshi Shibuya; Wataru Kitagawa; Mitsuji Nagahama; Kazuo Shimizu; Koichi Ito
Journal:  World J Surg       Date:  2015-07       Impact factor: 3.352

Review 4.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

5.  Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies.

Authors:  F Pacini; F Basolo; R Bellantone; G Boni; M A Cannizzaro; M De Palma; C Durante; R Elisei; G Fadda; A Frasoldati; L Fugazzola; R Guglielmi; C P Lombardi; P Miccoli; E Papini; G Pellegriti; L Pezzullo; A Pontecorvi; M Salvatori; E Seregni; P Vitti
Journal:  J Endocrinol Invest       Date:  2018-05-04       Impact factor: 4.256

6.  Papillary thyroid carcinoma of a diffuse sclerosing variant: ultrasonographic monitoring from a normal thyroid gland to mass formation.

Authors:  Hye Seong Kim; Boo-Kyung Han; Jung Hee Shin; Eun Young Ko; Chang Ohk Sung; Young Lyun Oh; Sang Yong Song
Journal:  Korean J Radiol       Date:  2010-08-27       Impact factor: 3.500

7.  Low expression of sodium iodide symporter expression in aggressive variants of papillary thyroid carcinoma.

Authors:  Songfeng Wei; Ming Gao; Cui Zhao; Yi Pan; Haixin Li; Jian Li; Xiaolong Li
Journal:  Int J Clin Oncol       Date:  2013-10-05       Impact factor: 3.402

8.  Aggressive variants of papillary thyroid microcarcinoma are associated with extrathyroidal spread and lymph-node metastases: a population-level analysis.

Authors:  Eric J Kuo; Paolo Goffredo; Julie A Sosa; Sanziana A Roman
Journal:  Thyroid       Date:  2013-09-14       Impact factor: 6.568

Review 9.  Thyroid Carcinoma: Phenotypic Features, Underlying Biology and Potential Relevance for Targeting Therapy.

Authors:  Jinwei Hu; Isabella J Yuan; Saied Mirshahidi; Alfred Simental; Steve C Lee; Xiangpeng Yuan
Journal:  Int J Mol Sci       Date:  2021-02-16       Impact factor: 5.923

10.  Clinicopathological Characteristics and Recurrence-Free Survival of Rare Variants of Papillary Thyroid Carcinomas in Korea: A Retrospective Study.

Authors:  Mijin Kim; Sun Wook Cho; Young Joo Park; Hwa Young Ahn; Hee Sung Kim; Yong Joon Suh; Dughyun Choi; Bu Kyung Kim; Go Eun Yang; Il-Seok Park; Ka Hee Yi; Chan Kwon Jung; Bo Hyun Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.